Unsupported Browser. Please use Google Chrome, Mozilla Firefox,
or Microsoft Edge to submit meeting requests. Microsoft Internet Explorer is not
supported due to its outdated JavaScript engine.
-
SoftBank Plans to Invest Billions in Biotech Stocks
-
In search of 'household healthcare brands of the future,' Foresite Capital raises $969M to satiate a tech-heavy appetite
-
OrbiMed, biopharma's biggest investor, closes $3.5B in three new private funds
-
Broadridge 2021 EDGAR Filing Calendar
-
Interview with Juergen Horn, Invetx - Part of the Name Tag Series
-
Jean Kim left Deerfield.
-
Interview with Jonathan Solomon, BiomX - Part of the Nametag Series
-
Follow Solebury Trout’s life sciences account on Twitter at @ST_LifeSciences
-
Interview with Dale Chappell, Humanigen - Part of the Nametag Series
-
Interview with Jonathan Drachman, Neoleukin Therapeutics - Part of the Nametag Series
-
Christian Richard left Tekla Capital Management LLC and joined Samsara BioCapital as Head of Public Research
-
Eliana Merle joined UBS as Analyst
-
Interview with Brandi Roberts, Lineage Cell Therapeutics - Part of the Nametag Series
-
Interview with Richard Godfrey, BerGenBio - Part of the NameTag Series - Update
-
Interview with Pawel Przewiezlikowski, Ryvu - Part of the Name Tag Series
-
Interview with David Parkinson, ESSA Pharma - Part of the Name Tag Series
-
Interview with Lucy Lu, Kintor Pharmaceutical - Part of the Name Tag Series
-
Scoop: SR One crew completes a complicated spinout from GlaxoSmithKline. And now they have a $500M fund to invest on their own
-
Michelle Levine joined Solasta Ventures in Boston as an Associate
-
Ronald Hsu left Artican Partners
-
CityWire - Star healthcare PM named next Wellington CEO
-
Interview with Theresa Heah, Asclepix - Part of the NameTag Series
-
Interview with Alex Zapesochny, Clerio Vision - Part of the NameTag Series
-
Interview with Vishal Doshi, AUM Biosciences - Part of the NameTag Series
-
Interview with Niquette Hunt, Candesant - Part of the NameTag Series
-
Interview with Zach Hornby, Boundless Bio - Part of the NameTag Series
-
Interview with Bob Geho, Diasome - Part of the NameTag Series
-
Interview with Bill Enright, Vaccitech - Part of the NameTag Series
-
Interview with Richard Andrews, Azitra - Part of the NameTag Series
-
Listen to Panels from our European Biotech Investor Day 2020
-
Life Sci VC - The Record-Breaking Biotech Funding Tsunami Of 1H2020
-
A new venture fund amid a pandemic? In the Nordics? Eir Ventures brings it on with €76M first close
-
SEC Proposes Amendments to Update Form 13F for Institutional Investment Managers; Amend Reporting Threshold to Reflect Today’s Equities Markets
-
OrbiMed Alum Maps Biotech Push
-
EndpointNews - The pandemic IPOs keep rolling, as Generation, Avidity, Vaxcyte each claim 200M+
-
Slanix Alex, Pharm.D. left Consonance Capital Management LP
-
Derek Yuan left QUAD Investments
-
Filed S-1/A: Vaxcyte Launches 14mm Share IPO with $14-$16 Marketing Range
-
Filed S-1/A: Avidity Biosciences Launches 10mm Share IPO with $14-$16 Marketing Range
-
Filed S-1/A: Generation Bio Launches 7.4mm Share IPO with $16-$18 Marketing Range
-
IPO Filings - 4 Offerings
-
Endpoints - Atlas raises new $400M fund amid spree of VC raises. Here’s what they’ll spend it on
-
Forma Therapeutics File $150mm IPO
-
Repare Therapeutics File $100mm IPO
-
Check out the latest podcast in the NameTag series with Takashi Kei Kishimoto from Selecta Bio
-
Filed S-1/A: Pliant Therapeutics Launches 6mm Share IPO with $14-$16 Marketing Range
-
Generation Bio File $125mm IPO
-
Avidity Biosciences File $100mm IPO
-
Filed S-1/A: Inari Medical Launches 7.3mm Share IPO with $14-$16 Marketing Range
-
Interview with Melissa Epperly, Zentalis - Part of the NameTag Series
